

## Expert Second Opinion: Investigators Provide Perspectives on the Best-Practice Management of Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Torvutatug samrotecan (AZD5335) is a novel agent that may best be described as a topoisomerase I antibody-drug conjugate targeting what?**
  - CDH6
  - TROP2
  - FR $\alpha$
- Data from the Phase III ROSELLA trial comparing relacorilant with *nab* paclitaxel to *nab* paclitaxel alone for patients with platinum-resistant ovarian cancer report which of the following outcomes with the combination?**
  - A progression-free survival (PFS) benefit but not an overall survival (OS) benefit
  - A PFS benefit and an OS benefit
  - Neither a PFS benefit nor an OS benefit
- On the basis of results from the Phase III KEYNOTE-B96 trial, pembrolizumab in combination with paclitaxel with or without bevacizumab was approved by the FDA for which patients with advanced ovarian cancer?**
  - All patients with platinum-resistant ovarian cancer after 1 or 2 prior systemic treatment regimens
  - Patients with platinum-resistant ovarian cancer and a PD-L1 CPS of 1 or higher after 1 or 2 prior systemic treatment regimens
  - Patients with platinum-resistant ovarian cancer and a PD-L1 CPS of 10 or higher after 1 or 2 prior systemic treatment regimens
- Results from the Phase III KEYNOTE-B96 trial evaluating the addition of pembrolizumab to weekly paclitaxel with or without bevacizumab for patients with platinum-resistant advanced ovarian cancer reported which efficacy finding?**
  - A statistically significant improvement in OS for only those patients whose tumors express PD-L1
  - A statistically significant improvement in OS for all-comers
  - No significant difference in OS
- The Phase II BELLA study is evaluating relacorilant in combination with which of the following agents in platinum-sensitive and platinum-resistant recurrent ovarian cancer?**
  - Weekly paclitaxel
  - nab* paclitaxel and bevacizumab
  - Pembrolizumab and chemotherapy